China Blood Products Industry Report, 2010
  • Nov/2010
  • Hard Copy
  • USD $1,500
  • Pages:59
  • Single User License
    (PDF Unprintable)       
  • USD $1,600
  • Code: YF008
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $2,400
  • Hard Copy + Single User License
  • USD $1,700
      
In 2009, Chinese blood products market valued nearly RMB7 billion and it will continue to expand in the next two or three years. The main reasons include:

  • The demand from the downstream of China blood products industry keeps growing.
  • China has a large population, and the aging of which grows obviously severe
  • The indications of blood products are increasing.
Due to the strong demand for albumin in China, the product structure of blood products in China distinguishes from foreign product structure which is dominated by coagulation factor. In 2009, in the product structure of blood products in China, albumin accounted for 68%, intravenous gammaglobulin 21% and coagulation factor 9%.

Product Structure of Blood Products in China, 2009
 2010111001.gif
Source: ResearchInChina

By the end of 2009, 33 Chinese manufacturers of blood products had obtained GMP certification, with the annual plasma volume of around 3,500 tons totally. However, only Hualan Biological Engineering Ltd, Beijing Tiantan Biological Products Co., Ltd, Shanghai RAAS Blood Products Co., Ltd, Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd, Sino Biopharmaceutical Limited and CNBG Shanghai Institute of Biological Products have the annual plasma volume of over 300 tons respectively.

Hualan Biological Engineering Ltd, as a leading enterprise in China blood products industry, owns a lot of plasma stations and relatively abundant plasma resources with high utilization rate and many varieties. As of October 2010, Hualan Biological Engineering Ltd had had 18 plasma stations, including 13 plasma collection stations in operation, one being examined, 3 under construction and one to be built.

From January to August of 2010, human serum albumin, intravenous human immunoglobulin, tetanus human immunoglobulin, hepatitis B immunoglobulin, human immunoglobulin, human prothrombin complex, rabies immunoglobulin and human clotting Factor VIII of Hualan Biological Engineering Ltd were approved by National Institute for the Control of Pharmaceutical And Biological Products, with the total release volume of 2.272 million bottles.

From January to June of 2010, Hualan Biological Engineering Ltd achieved the revenue of RMB343 million from blood products (a 67% YoY rise), including RMB124 million from human serum albumin (a 13% YoY rise), RMB121 million from intravenous gammaglobulin (a 61% YoY rise) and RMB97.95 million from other products (a 38% YoY rise).

   Gross Margin of Hualan Biological Engineering Ltd (by Product), 2007- H1 2010
 2010111002.gif
Source: ResearchInChina, Hualan Biological Engineering Ltd
1 Profile of Blood Products
1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features

2 Overview of China Blood Products Industry
2.1 General Overview
2.2 Operating Environment
2.2.1 International Market
2.2.2 Policies
2.2.3 Domestic Biopharmaceutical Market
2.3 Plasma Volume
2.4 Import & Export

3 Main Blood Product Markets 
3.1 Human Serum Albumin
3.2 Intravenous Human Immunoglobulin
3.3 Coagulation Factor 
3.4 Hepatitis B Immunoglobulin
3.5 Human Immunoglobulin 
3.6 Human Prothrombin Complex
3.7 Tetanus Immunoglobulin
3.8 Rabies Immunoglobulin

4 Key Manufacturers in China 
4.1  Hualan Biological Engineering Ltd
4.1.1 Profile
4.1.2 Operation
4.1.3 Blood Products
4.2 Shanghai RAAS Blood Products Co., Ltd
4.2.1 Profile
4.2.2 Operation
4.2.3 Strategies
4.3 Beijing Tiantan Biological Products Co., Ltd 
4.3.1 Profile
4.3.2 Operation
4.3.3 Blood Products
4.4 Sino Biopharmaceutical Limited
4.4.1 Profile
4.4.2 Operation
4.4.3 Shandong Taibang Biological Products Co. Ltd
4.4.4 Xi’an Hui Tian Blood Products Co. Ltd
4.4.5 Guiyang Qianfeng Biological Product Liability Co., Ltd.
4.5 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd
4.5.1 Profile
4.5.2 Operation
4.6 CNBG Shanghai Institute of Biological Products
4.6.1 Profile
4.6.2 Operation
4.7 Shanxi Kangbao Biological Product Co., Ltd
4.7.1 Profile
4.7.2 Operation
4.8 Green Cross
4.8.1 Profile
4.8.2 Operation
4.9 Jiangxi Boya Biopharmaceutical Co., Ltd
4.9.1 Profile
4.9.2 Operation
Classification and Effects of Blood Products
Comparison between Gene Recombinant Blood Products and Traditional Blood Products
Blood Product Industry Chain
Blood Products Market Scale in China, 2003-2009
Product Structure of Blood Products in China, 2009
Product Structure of International Blood Products , 2009
Market Shares of Blood Products Manufacturing Enterprises in China, 2009
Product Lines Contrast of Blood Products Manufacturing Enterprises in China
Release Volume of Blood Products in China, 2007-Aug. 2010
Global Blood Products Market Scale, 2003-2008
Classification of Global Blood Products Manufacturing Enterprises
Sales of Global Blood Products Giants, 2009
Major Policies for Blood Products in China
Sales Revenue and YoY Growth Rate of Biological and Biochemical Pharmacy in China, 2005-2009
Annual Plasma Volume in China, 2002-2009
Production of Blood Products Manufacturing Enterprises in China, 2009
Major Manufacturers and Their Shares in Chinese Human Serum Albumin Market, 2009
Major Manufacturers and Their Shares in Chinese Intravenous Human Immunoglobulin Market, 2009
Per Capita Consumption of Intravenous Human Immunoglobulin in Some Countries and Regions, 2005
Major Manufacturers and Their Shares in Chinese Human Clotting Factor VIII Market, 2009
Major Manufacturers and Their Release Volume & Shares in Chinese Hepatitis B Immunoglobulin Market, 2009
Major Manufacturers and Their Shares in Chinese Human Immunoglobulin Market, 2009
Major Manufacturers and Their Shares in Chinese Human Prothrombin Complex Market, 2009
Major Manufacturers and Their Release Volume in Chinese Tetanus Immunoglobulin Market, 2009
Major Manufacturers and Their Release Volume in Chinese Rabies Immunoglobulin Market, 2009
Operating Income and Net Income of Hualan Biological Engineering Ltd, 2006- H1 2010 
Operating Income of Hualan Biological Engineering Ltd (by Sector), 2007- H1 2010
Operating Income of Hualan Biological Engineering Ltd (by Region), 2007-2009
Gross Margin of Hualan Biological Engineering Ltd (by Product) , 2007- H1 2010
Distribution of Plasma Collection Stations of Hualan Biological Engineering Ltd, by Oct. 2010
Release Volume of Blood Products of Hualan Biological Engineering Ltd, 2007- Aug. 2010
Operating Income of Blood Products of Hualan Biological Engineering Ltd (by Product), 2007- H1 2010
Operating Income and Net Income of Shanghai RAAS Blood Products Co., Ltd, 2006- H1 2010    
Release Volume of Blood Products of Shanghai RAAS Blood Products Co., Ltd, 2007- Aug. 2010     
Operating Income of Shanghai RAAS Blood Products Co., Ltd (by Product), 2005- H1 2010
Gross Margin of Shanghai RAAS Blood Products Co., Ltd (by Product), 2005-2009
Plasma Volume of Shanghai RAAS Blood Products Co., Ltd, 2007-2011E
Operating Income of Shanghai RAAS Blood Products Co., Ltd (by Region), 2008-2009
Operating Income and Net Income of Beijing Tiantan Biological Products Co., Ltd, 2006- Q3 2010   
Operating Income of Beijing Tiantan Biological Products Co., Ltd  (by Product) , 2007-2009
Gross Margin of Beijing Tiantan Biological Products Co., Ltd  (by Product) , 2007-2009
Operating Income of Beijing Tiantan Biological Products Co., Ltd  (by Region), 2007-2009
Operating Income of Blood Products of Beijing Tiantan Biological Products Co., Ltd , 2007- H1 2010 
Operating Income and Gross Profit of Sino Biopharmaceutical Limited, 2007- Q2 2010
Operating Income of Sino Biopharmaceutical Limited (by Product), 2007-2009
Operating Income and Total Profit of Shandong Taibang Biological Products Co. Ltd, 2007-2008
Operating Income and Total Profit of Xi’an Hui Tian Blood Products Co. Ltd, 2007-2008
Operating Income and Total Profit of Guiyang Qianfeng Biological Product Liability Co., Ltd., 2007-2008
Release Volume of Blood Products of Guiyang Qianfeng Biological Product Liability Co., Ltd., 2007-Aug. 2010 
Operating Income and Total Profit of Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd, 2007-2008
Release Volume of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd, 2007-Aug. 2010
Operating Income and Total Profit of CNBG Shanghai Institute of Biological Products, 2007-2008
Release Volume of Blood Products of CNBG Shanghai Institute of Biological Products, 2007-Aug .2010
Operating Income and Total Profit of Shanxi Kangbao Biological Products Co., Ltd, 2007-2008
Release Volume of Blood Products of Shanxi Kangbao Biological Products Co., Ltd, 2007-Aug. 2010
Operating Income and Total Profit of Green Cross (China) , 2007-2008
Release Volume of Blood Products of Green Cross (China), 2007- Aug. 2010
Operating Income and Total Profit of Jiangxi Boya Biopharmaceutical Co., Ltd., 2007-2008
Release Volume of Blood Products of Jiangxi Boya Biopharmaceutical Co., Ltd., 2007- Aug. 2010

Global and China DNA Sequencing Industry Research Report, 2014-2017

DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a...

Global and China Stem Cell Industry Report, 2014-2017

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatmen...

China Human Vaccine Industry Report, 2014-2017

Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlie...

China Blood Product Industry Report, 2014-2017

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption t...

China Animal Vaccine Industry Report, 2013-2016

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main ...

China Contract Research Organization (CRO) Industry Report, 2013-2016

China CRO industry has developed rapidly in recent years, registering a CAGR of 27.2% during 2007-2013, of which the market size reached RMB 36 billion in 2013, occupying 10% of global market share. ...

Global and China Biodegradable Plastics Industry Report, 2013-2016

Global biodegradable plastic production and demand have grown rapidly in recent years, and the capacity reached 1-1.5 million t/a in 2012-2013. Among dozens of biodegradable plastic varieties develope...

Global and China Industrial Enzyme Industry Report, 2014-2016

In 2007-2013, the global industrial enzyme market size grew at the CAGR of 5.7%, reaching USD4.04 billion in 2013, 1.4 times that in 2007. The global industrial enzyme market is monopolized by a small...

China Heparin Industry Report, 2013-2015

Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradual...

China Lactic Acid and Derivative Industry Report, 2013

China’s lactic acid capacity and output continued to grow at the respective CAGR of 22.7% and 28.7% in 2007-2011. But limited by market demand, the annual output of most vendors was below their design...

China Human Vaccine Industry Report, 2012-2015

In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the...

China Blood Product Industry Report, 2012-2015

Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due...

China Animal Vaccine Industry Report, 2012-2015

In view of the frequent occurrence of animal epidemic diseases over the years, the Chinese government has increased investment in epidemic prevention and implemented compulsory immunization system. Be...

Global and China Monoclonal Antibody Industry Report, 2013

In recent years, the monoclonal antibody market around the globe has witnessed substantial growth, and the CAGR of market scale during 1997-2011 has reached 44% approximately. It is predicted that the...

China Insulin Industry Report, 2012-2015

China is a country with the largest number of diabetics. In 2011, the market scale of diabetes medicine in China approximated RMB13.8 billion, of which, insulin medicines mainly comprising recombinant...

China Heparin Industry Report, 2012-2014

China, abundant in heparin raw materials, has become one of the world’s largest heparin API producers and exporters, owning to the quality of heparin API having won international recognition gradually...

Global and China Industrial Enzyme Industry Report, 2012-2014

Industrial enzyme which refers to the enzyme preparation used for industrial purposes can be applied to detergent, animal feed, bread, brewing (beer, wine, etc.), papermaking, textile, bio-ethanol and...

China Blood Products Industry Report, 2011-2012

Blood plasma serves as key raw material in blood product industry. In August 2011, the shut-down of 16 plasma collection stations in Guizhou province, China resulted in a YoY decline of 15% in plasma ...

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号
在线客服系统